GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Accumulated other comprehensive income (loss)

STTK (Shattuck Labs) Accumulated other comprehensive income (loss) : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Shattuck Labs's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was $0.00 Mil.

Shattuck Labs's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2024 ($0.05 Mil) to Dec. 2024 ($0.00 Mil) and declined from Dec. 2024 ($0.00 Mil) to Mar. 2025 ($0.00 Mil).

Shattuck Labs's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 ($-0.88 Mil) to Dec. 2023 ($0.00 Mil) but then declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).


Shattuck Labs Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Shattuck Labs's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Accumulated other comprehensive income (loss) Chart

Shattuck Labs Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial -0.06 -0.56 -0.88 - -

Shattuck Labs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 0.05 - -

Shattuck Labs Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


Shattuck Labs Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shattuck Labs Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Accumulated other comprehensive income (loss)
Traded in Other Exchanges
N/A
Address
500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Executives
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Taylor Schreiber director, officer: Chief Executive Officer 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Tyler Brous director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Stephen Stout officer: See Remarks C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Andrew R Neill officer: See Remarks 1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla officer: Chief Technical Officer 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein director 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson officer: General Counsel 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower director, 10 percent owner, officer: Chairman 3317 BOWMAN AVE, AUSTIN TX 78703
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Arundathy N. Pandite officer: Chief Medical Officer 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung officer: Chief Business Officer C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744